睿知中国医院研究地图
候选清单

正在招募白塞病III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

ClinicalTrials.gov 上登记的一项白塞病开放试验。牵头方不是本站收录的医院;本站收录的 20 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 20

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心桂林医学院附属医院Affiliated Hospital of Guilin Medical University桂林医院页面
  2. 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
  3. 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
  4. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  5. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  6. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  7. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  8. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  9. 研究中心广东省第二人民医院Guangdong Second Provincial General Hospital广州医院页面
  10. 研究中心临沂市人民医院Linyi People's Hospital临沂医院页面
  11. 研究中心北京大学第一医院Peking University First Hospital北京医院页面
  12. 研究中心北京大学人民医院Peking University People's Hospital北京医院页面
  13. 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
  14. 研究中心河北医科大学第二医院Second Hospital of Hebei Medical University石家庄医院页面
  15. 研究中心山西医科大学第二医院Second Hospital of Shanxi Medical University太原医院页面
  16. 研究中心中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面
  17. 研究中心香港大学深圳医院The University of Hong Kong–Shenzhen Hospital深圳医院页面
  18. 研究中心中山大学附属第三医院Third Affiliated Hospital of Sun Yat-sen University广州医院页面
  19. 研究中心同济大学附属同济医院Tongji Hospital上海医院页面
  20. 研究中心首都医科大学宣武医院Xuanwu Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06145893,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Currently having a malignant tumor, or a history of any malignant tumor within 5 years prior to screening (except for treatment-experienced squamous cell carcinoma in situ of the skin, basal cell carcinoma or cervical carcinoma in situ with no evidence of relapse within the past 12 months);

    排除标准第 27 条

  3. Hemoglobin ≤85g/L;

    排除标准第 15 条

    Platelets <100×10\^9/L;

    排除标准第 17 条

    Serum creatinine >1.5 mg/dL (>132.6 μmol/L);

    排除标准第 18 条

    Total bilirubin of >2.0 mg/dL (>34.2 μmol/L);

    排除标准第 19 条

    Both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥1.5×ULN; Note: The above tests can be repeated at most once during the screening period. If the result within 2 weeks prior to randomization falls into the specified range, the subject is eligible for the study;

    排除标准第 20 条

  4. Active lesions associated with BD in major organs requiring immunosuppressive treatment, e.g., those in lungs (e.g., pulmonary aneurysm), blood vessels (e.g., thrombophlebitis, recurrent malignant aneurysms), gastrointestinal tract (e.g., gastrointestinal ulcers), and central nervous system (e.g., meningoencephalitis); Note: Patients with refractory BD who experienced gastrointestinal perforation, active bleeding, or obstruction, etc. within 3 months prior to randomization are to be excluded.

    排除标准第 1 条

    Positive for human immunodeficiency virus (HIV) antibody or treponema pallidum antibody test;

    排除标准第 26 条

  5. Throughout the study period from signing of ICF through 3 months after the last study dose, women of childbearing potential and male subjects who have not undergone vasoligation should use effective contraceptive measures, including vasoligation, abstinence, intrauterine device (IUD), hormones (oral, patches, rings, injections, implants) and barrier methods (diaphragms, cervical caps, sponges, condoms);

    入选标准第 8 条

    Female subjects who are pregnant or breast feeding;

    排除标准第 33 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06145893,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Understanding and voluntarily signing the Informed Consent Form (ICF) for this study;
  2. Age 18-75 years (inclusive), male or female;
  3. Diagnosed as BD based on the ICBD-2013;
  4. At least 2 oral ulcers present at V1 (screening), and:
  5. at least 2 oral ulcers present at V2 (the day of randomization) when V2 occurs 14-56 days after V1; OR
  6. at least 3 oral ulcers present at V2 (the day of randomization) when V2 occurs 0-13 days after V1;
  7. Applicability of systemic treatment for oral ulcers: Based on the severity of the disease and the involved area, the investigator determines that the patient's oral ulceration is not suitable for topical treatment or that the patient's oral ulceration cannot be effectively controlled by topical treatment, so that systemic treatment is to be used;
  8. Throughout the study period from signing of ICF through 3 months after the last study dose, women of childbearing potential and male subjects who have not undergone vasoligation should use effective contraceptive measures, including vasoligation, abstinence, intrauterine device (IUD), hormones (oral, patches, rings, injections, implants) and barrier methods (diaphragms, cervical caps, sponges, condoms);
  9. Being able to comply with the follow-up schedule and other protocol requirements.

排除标准:Exclusion Criteria:

  1. Active lesions associated with BD in major organs requiring immunosuppressive treatment, e.g., those in lungs (e.g., pulmonary aneurysm), blood vessels (e.g., thrombophlebitis, recurrent malignant aneurysms), gastrointestinal tract (e.g., gastrointestinal ulcers), and central nervous system (e.g., meningoencephalitis); Note: Patients with refractory BD who experienced gastrointestinal perforation, active bleeding, or obstruction, etc. within 3 months prior to randomization are to be excluded.
  2. Any clinically significant heart disease (including but not limited to: unstable ischemic heart disease, NYHA III/IV left ventricular failure, or myocardial infarction) or clinically significant 12-lead ECG abnormalities detected during the 6 months prior to screening, which, at the investigator's discretion, may put the subject at safety risk or may interfere with the study assessments;
  3. Use of the following immunomodulatory therapies:
  4. Colchicine within 7 days prior to randomization;
  5. Perazathioprine, mycophenolate, baritinib, or tofacitinib within 10 days prior to randomization;
  6. Cyclosporine, methotrexate, cyclophosphamide, thalidomide, or dapsone within 4 weeks (28 days) prior to randomization;
  7. Biologics within 5 half-lives prior to randomization, e.g.:
  8. Etanercept within 4 weeks prior to randomization;
  9. Infliximab or leflunomide within 8 weeks prior to randomization;
  10. Adalimumab, golimumab, abatacept, or tolizumab within 10 weeks prior to randomization;
  11. Secukinumab within 6 months prior to randomization;
  12. Intraarticular or systemic corticosteroid treatment prior to randomization and within 5 pharmacokinetic/pharmacodynamic half-lives; Note: For subjects with eye symptoms, glucocorticoid eye drops are allowed throughout the trial (except for within 24 hours prior to a trial visit).
  13. Chinese patent medicines with immunomodulatory effect within 2 weeks prior to randomization; any Chinese pate nt medicines or decoctions within 2 weeks prior to randomization that might affect efficacy evaluation, or containing sinomenine, total glucoside of paeony, or tripterygium wilfordii, etc.;
  14. Laboratory tests:
  15. Hemoglobin ≤85g/L;
  16. White blood cell count <3.0×10\^9/L or >14×10\^9/L;
  17. Platelets <100×10\^9/L;
  18. Serum creatinine >1.5 mg/dL (>132.6 μmol/L);
  19. Total bilirubin of >2.0 mg/dL (>34.2 μmol/L);
  20. Both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥1.5×ULN; Note: The above tests can be repeated at most once during the screening period. If the result within 2 weeks prior to randomization falls into the specified range, the subject is eligible for the study;
  21. Use of potent inducers of cytochrome P450 enzymes (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin sodium) within 4 weeks prior to randomization;
  22. Other autoimmune diseases or chronic inflammatory diseases associated with immunity, e.g., rheumatic fever, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, Sjögren's syndrome, and inflammatory bowel disease;
  23. Currently active infections or recurrent bacterial, fungal, viral, mycobacterial or other infectious diseases (including but not limited to tuberculosis, atypical mycobacteriosis, hepatitis B, hepatitis C, herpes zoster, histoplasmosis, and coccidiosis; however, onychomycosis is excluded), which, at the investigator's discretion, may put the subject at safety risk; Note: Subjects positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, or with a history of active mycobacterial infection of any species (including Mycobacterium tuberculosis) within 3 years prior to screening visit should be excluded. Screening is permitted if the subject has been cured for at least 3 years prior to randomization with documentation available for verification;
  24. Clinically significant chest X-ray or CT abnormalities, which, at the investigator's discretion, may put the subject at safety risk; Note: If a chest X-ray or CT was performed within 3 months prior to V1, the examination may be omitted for V1;
  25. History of transplantation or immunodeficiency;
  26. Positive for human immunodeficiency virus (HIV) antibody or treponema pallidum antibody test;
  27. Currently having a malignant tumor, or a history of any malignant tumor within 5 years prior to screening (except for treatment-experienced squamous cell carcinoma in situ of the skin, basal cell carcinoma or cervical carcinoma in situ with no evidence of relapse within the past 12 months);
  28. Use of any clinical investigational product within 4 weeks prior to randomization or 5 pharmacokinetic/pharmacodynamic half-lives, whichever is longer; Note: Subjects who have participated in HM005BD2S01 study are not eligible to participate in this trial;
  29. Known allergy to the study drug or any of its components or allergic constitution;
  30. A history of alcohol or drug abuse or dependence, or psychiatric disorder;
  31. Any conditions that may interfere with oral drug absorption, e.g., subtotal gastrectomy, clinically significant diabetic gastrointestinal disease, or certain types of bariatric surgery such as gastric bypass surgery, not including procedures that simply separate the stomach into separate chambers such as gastric banding surgery;
  32. Prior use of apremilast;
  33. Female subjects who are pregnant or breast feeding;
  34. Concomitant serious, progressive, or uncontrolled diseases, with which participation in the study may, at the investigator's discretion, put the subject at potential risk or affect the interpretation of study results.

引自 ClinicalTrials.gov, NCT06145893, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06145893,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06145893